Pherexa
Webpherexa没有显示pfs和os之间的一致性。os增加的根本原因是pfs效应不明显；然而，仍不能低估os作为研究终点的重要性。两组之间卡培他滨的剂量差异很小，不太可能是影响预后 … Web4. dec 2009 · A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab, in Patients With HER2 …
Pherexa
Did you know?
WebPHEREXA je dosud probíhající randomizovaná, dvojitě zaslepená studie fáze II, která hodnotí soubor pacientek s HER2-pozitivním karcinomem prsu, u nichž došlo k progresi … http://www.biovip.com/mednews/202405/41086.shtml
Web11. okt 2024 · Still, PHEREXA is formally a negative study and T-DM1 therefore remains the standard-of-care in the second-line setting. Brain metastases (BM) are a common and devastating complication of HER2-positive MBC. Guidelines recommend the continuation of systemic therapy in case of isolated central nervous system (CNS) progression and … Web30. máj 2024 · Overall survival (OS) is assessed in an exploratory analysis of pts who either received or did not receive T-DM1 at any time after discontinuing study-assigned tx in …
Web30. máj 2024 · Overall survival (OS) is assessed in an exploratory analysis of pts who either received or did not receive T-DM1 at any time after discontinuing study-assigned tx in CLEOPATRA or PHEREXA. 1023Background: T-DM1 was approved for pts with HER2+ MBC previously treated with trastuzumab (H) and a taxane based on the phase III EMILIA study. … Web4. sep 2024 · PHENIX研究：脑转移患者接受吡咯替尼联合卡培他滨获益显著. PHENIX研究结果显示：吡咯替尼方案可有效抑制脑转移的发生和进展，与对照组相比，新发脑转移比 …
Web1. máj 2014 · Antibody–drug conjugates, comprising a potent cytotoxic molecule linked to a target-specific antibody, are a class of therapeutic agents that potentially reduce systemic …
Web11. okt 2024 · Although formally negative, overall survival data from the PHEREXA trial suggest clinical activity of dual HER2-inhibition with trastuzumab and pertuzumab in patients with prior trastuzumab ... marvin erickson obituaryWeb1. jan 2024 · Z hlediska genové exprese se rozlišují čtyři hlavní molekulární subtypy – luminal A, luminal B, HER2 enriched (HER2-E), basal-like. Nejčastějším subtypem je HER2-E (50– 60 %). U hormonálně dependentních (HR+) HER2 pozitivních nádorů představuje podskupina HER2-E 40– 50 %, ostatní jsou luminální A a B podtypy. huntingdon tennessee crime statsWebPHEREXA: Survival Data Capecitabine (X) + trastuzumab (H) Eligibility • HER 2+ m. BC • Prior treatment with taxane • Progression on 1 st-line trastuzumab-based therapy Median PFS by IRF Median OS (mo) R X + H + pertuzumab (P) H+X (n = 224 ) H+X+P (n = 228) Hazard ratio p-value 9. 0 mo 11. 1 mo 0. 82 0. 07 28. 1 36. 1 0. 68 NE IRF = independent review facility; … marvin e pratt elementary school